UBS Survey Shows Signs of Strength for Gilead's (GILD) TAF

May 17, 2013 1:00 PM EDT Send to a Friend
Get Alerts GILD Hot Sheet
Price: $110.71 +3.29%

Rating Summary:
    23 Buy, 5 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 24 | Down: 28 | New: 14
Trade GILD Now!
Join SI Premium – FREE
UBS today maintained a Buy rating on Gilead Sciences (NASDAQ: GILD) and raised its price target to $67.00 (from $63.00). Analyst Matthew Roden sees ongoing strength for its HIV franchise.

"Ahead of the second ph2 result expected near term for tenofovir alafenamide (TAF), a next-gen replacement for Viread, we spoke to 2 HIV experts and conducted a survey of top-volume prescribers to gauge initial receptiveness and expected utilization once available. Results were highly supportive of TAF, but also for GlaxoSmithKline's (NYSE: GSK) dolutegravir, which will compete against GILD's Stribild," said Roden.

For an analyst ratings summary and ratings history on Gilead Sciences (NASDAQ: GILD) click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $54.96 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

UBS

Add Your Comment